Search - tctmd.com

Displaying 141 - 151 of 151

Sort: Relevancy | Date

Presentation ESC 2012

WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)

Presenter: Willem Dewilde

August 28, 2012

News Conference News ESC 2012

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

Yael L. Maxwell

August 28, 2012

Presentation ESC 2012

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction

Presenter: 205474|Benjamin Scirica

August 26, 2012

News Conference News ESC 2012

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

August 26, 2012

News Conference News ESC 2012

ESC Congress 2012 Offers Slate of Guidelines, New MI Definition

Caitlin E. Cox

August 26, 2012

News Conference News

Japanese ACS Patients Fare Better with High Rates of Intensive Treatment

September 01, 2011

News Conference News

Halting Clopidogrel in First Year Following Acute MI Hazardous

September 01, 2011

News Conference News

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

August 31, 2011

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

News Conference News

Novel Anticoagulants Showing Benefits in A-fib Subgroups

August 29, 2011

News Conference News

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

August 28, 2011

Advertisement

WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

ESC Congress 2012 Offers Slate of Guidelines, New MI Definition

Japanese ACS Patients Fare Better with High Rates of Intensive Treatment

Halting Clopidogrel in First Year Following Acute MI Hazardous

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

Long-term Antiplatelet Therapy: All Risk, No Benefit

Novel Anticoagulants Showing Benefits in A-fib Subgroups

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content